Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

CANADA: Feasibility of Incorporating Self-Collected Rectal Swabs into a Community Venue-Based Survey to Measure the Prevalence of HPV Infection in Men Who Have Sex with Men




 

Sexually Transmitted Diseases Vol. 38; No. 10: P. 964-969

Adding self-collected rectal swabs (SCRS) to existing community venue-based HIV surveillance systems for MSM may prove to be a feasible method for monitoring human papillomavirus vaccine-related outcomes among these men, wrote the authors. In the current study, the team measured HPV and anal dysplasia prevalence by incorporating SCRS into ManCount, the Vancouver site of the M-Track HIV surveillance system.

Self-collection kits for use onsite or at a follow-up venue were provided to participating MSM. The swabs were subject to polymerase chain reaction amplification for HPV detection; cytology slides were reviewed for anal dysplasia. Multivariate logistic regression was used to identify factors associated with participation.

Of 766 men completing ManCount, 268 (35 percent) agreed to take part. These men self-collected 252 specimens (247 onsite), resulting in 239 complete specimens. Of these, 33.5 percent did not have detectable �-globin. In the remaining 159 specimens, the prevalence of HPV infection was 62.3 percent (23.3 percent HPV type 16 or 18; 38.4 percent HPV type 6, 11, 16 or 18). In the 62.3 percent (149) of specimens adequate for cytology, prevalence of anal dysplasia was 42.3 percent (HSIL 11.4 percent; LSIL 18.8 percent; ASC-US 6.7 percent; ASC-H 5.4 percent).

"Participation was associated with venue type, availability of onsite collection, and other characteristics," the authors wrote. "SCRS can be feasibly integrated within existing community venue-based HIV surveillance systems for MSM, and may be a suitable method for monitoring the impact of HPV vaccination in this population. However, participation may be influenced by venue type and availability of onsite collection, and adequacy of SCRS specimens may be lower in community venues as compared with clinical settings."



 


Copyright © 2011 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in November 9, 2011. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.